spacer
home > ict > winter 2014 > source code
PUBLICATIONS
International Clinical Trials

Source Code

ICT: Tell us a bit about your current role and its demands?

Nadia Whittley: I have joined Pharmarama at a pivotal point in its history: we need to build on past successes and look at how we can continue to remain a trusted, valuable partner for our customers. My role is to utilise existing internal strengths, and identify the new vision and strategy to get there.

To what extent does pharma find sourcing comparator drugs logistically difficult and an unwelcome distraction from running trials?

Escalating regulatory demands, rapid globalisation of studies and the complex handling needs of contemporary medicines mean that the relationship with a comparator supplier should no longer be simply transactional. Our customers demand flexibility, reliability and know-how as a means to overcome any distraction from the focus on running a trial. We believe that pharma companies, packagers and suppliers have to work in partnership before, during and after the clinical study to anticipate logistical challenges and leverage specialist knowledge on all sides.

Why have manufacturers started to make it difficult to acquire certain products – and how can this be overcome?

I like to see this from a different viewpoint. Recent legislation redirected manufacturers’ efforts towards strengthening their processes around traceability throughout the drug supply chain, and this is something we support entirely. Comparator suppliers like us have been working hard to develop a strong network with manufacturers by providing different levels of assurance with bona fide evidence that products will only be used as part of a valid trial, thereby ensuring continuous supply for clinical trials.

Some predict that quality issues, such as temperature control, will dominate comparator sourcing in future – do you agree?

Yes, this is one of the challenges we face. Maintaining the integrity of the supply chain goes hand-in-hand with ensuring the physical integrity of the medicines we handle. The use of dedicated temperature-mapped vehicles, GPS positioning and reporting, track and trace technologies and rigorous adherence to validated procedures will ensure the client’s goal of a quality delivery of comparator drug that meets study protocol, regulatory and budgetary requirements.

Part of your work involves supplying medicines that are unlicensed in the UK and those that have been discontinued – how does this work?

Typically, we refer to unlicensed medicines as ones which are licensed in one particular country but the manufacturer has chosen not to license it elsewhere, usually for commercial reasons. Specialists or GPs choose to prescribe unlicensed medicines to provide better therapeutic solutions for their patients; our job is to source this alternative in the most cost-effective way, following a rigorous and regulated process.

Critical shortage management is a service we provide in cases where medicines are either at the end of their lifecycle or are having supply issues. The need here is to provide continuity of treatment for patients, which is where our strong network of suppliers plays a critical role.

What new and innovative ways are you exploring to expand your business?

We have started to explore the concept of ‘value innovation’, which is to look at new ways to improve the value of our current portfolio, while bringing new and innovative services to meet the increasingly challenging demands of clinical trial management. For example, combating drug counterfeiting and ensuring supply chain integrity is vital if we want to remain the most secure partner for our customers and their patients. We are looking at how we can bring new technologies to the market and reinforce further our processes to offer our customers well-deserved peace of mind.



Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nadia Whittley is Chief Executive Officer of comparator drug sourcer, Pharmarama International. A seasoned senior executive with experience leading global teams in the medical device and healthcare sectors, Nadia previously worked for Allergan, Boston Scientific, Biotronik and Medtronic.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement